Akeso Drug Outperforms AstraZeneca's Imfinzi in Cancer Trial
Chinese biopharmaceutical firm Akeso announced its immunotherapy drug, ivonescimab, surpassed AstraZeneca’s Imfinzi in a Phase 3 trial for biliary tract cancer, showing extended patient survival.
Akeso Drug Demonstrates Superiority
Chinese biopharmaceutical firm Akeso reported its immunotherapy drug, ivonescimab, outperformed AstraZeneca's Imfinzi in a head-to-head Phase 3 clinical trial. The study focused on advanced biliary tract cancer, a particularly aggressive form. Akeso announced the results on Wednesday, via a Hong Kong stock exchange filing.
Patients receiving ivonescimab combined with chemotherapy lived longer than those on Imfinzi (durvalumab) plus chemotherapy. This outcome marks a significant advance for Akeso's research efforts.
Trial Details and Disease Severity
The trial included 682 patients diagnosed with advanced biliary tract cancer. This cancer type has a five-year survival rate below five per cent, according to a Nature study. Akeso’s ivonescimab has also demonstrated positive results in some lung cancer treatments. US firm Summit Therapeutics licensed ivonescimab in a previous multibillion-dollar agreement.
This latest outcome is the drug's first positive Phase 3 study for gastrointestinal tumours, expanding its potential application.
Broader Application Anticipated
Akeso's founder and CEO, Xia Yu, stated this positive result could allow ivonescimab to be used for a broader range of solid tumours. The company has not yet released the precise survival figures from the trial. Akeso expects to present these detailed results at an upcoming conference.
This success highlights China's growing biopharma industry, increasingly competing on a global scale with innovative treatments.
For Asian pharmaceutical firms, this trial outcome demonstrates the potential for homegrown innovation to challenge established global players. Akeso's success could attract further investment into China's biotechnology sector, driving research and development. It also positions Akeso and its US partner, Summit Therapeutics, for expanded market access in oncology.
Investors will monitor the forthcoming disclosure of detailed survival data for further clarity on the drug's efficacy and commercial prospects.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.